Testing a new drug combo for pancreatic cancer that cannot be surgically removed
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination of drugs (including an investigational immunotherapy and a targeted pill, plus standard chemotherapy) as the first treatment for pancreatic cancer that cannot be removed with surgery. It may help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a confirmed diagnosis of pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer).
- Your cancer has spread to other organs or is too close to major blood vessels to be removed with surgery.
- You are generally able to manage daily activities (ECOG score 0-1) and expected to live at least 3 months.
- You have not received prior chemotherapy or other systemic treatment for this cancer.
- Your blood counts and liver/kidney function are within required limits.
- You are willing to use effective birth control during the study and for 6 months after (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of drugs (an investigational immunotherapy, a targeted therapy, and chemotherapy) as a second-line treatment for people with advanced pancreatic cancer. The goal is to see if this combination can help slow down or stop the cancer when the first treatment no longer works.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.